ASBP
Aspire Biopharma Holdings, Inc.0.1043
-0.0031-2.89%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
14.44MP/E (TTM)
-Basic EPS (TTM)
-0.64Dividend Yield
0%Recent Filings
10-K
FY2025 results
Aspire Biopharma posted FY2025 net loss of $24.5M on $6K revenue from nascent Buzz Bomb caffeine sales in Q3-Q4, while ramping R&D expenses to $924K (up from $144K in 2024) for sublingual aspirin trials ending July with positive PK results versus oral aspirin. Q4 saw FDA pre-IND nod for next platelet inhibition study slated for mid-2026 ahead of 505(b)(2) NDA, but heavy G&A at $17.6M reflected recapitalization costs, note conversions, and Nasdaq compliance battles—resolved via February 2026 preferred raise yielding $11M gross. No debt lingers post-conversions; $100M ELOC stands ready. Yet clinical delays could stall momentum.
8-K
Aspire raises $11M preferred
Aspire Biopharma closed initial $11M raise via 13,750 Series A preferred shares on Feb 6, converting $944K debt while paying $900K placement fee. Deal boosts equity above Nasdaq's $2.5M threshold, yet needs shareholder nod for full conversion and second $10M tranche. Board swap: Fell out, Balatsos in.
8-K
Filed Series A Preferred designation
Aspire Biopharma filed a Certificate of Designation on February 2, 2026, creating 25,000 shares of Series A Convertible Preferred Stock under Item 5.03, tied to a Securities Purchase Agreement. Holders convert at 80% of the prior five-day low common stock price, floored at 20% of Nasdaq's Minimum Price, with 4.99% ownership cap (expandable to 9.99%). Senior to common on liquidation. Conversion needs shareholder approval beyond 19.99%.
8-K
Secures $2M OID debentures
8-K
Confirms 4.89M-share incentive plan
Aspire Biopharma confirmed terms of its 2024 Stock Incentive Plan on January 8, 2026, setting the share limit at 4,890,000 after stockholder approval in February 2025. Board approved RSU and option award forms for executives, directors, and employees, tying vesting to continued service. Equity pool now active. Plan aligns talent with shareholders.
AEON
AEON Biopharma, Inc.
1.03+0.17
ATHA
Athira Pharma, Inc.
3.88+0.03
CNSP
CNS Pharmaceuticals, Inc.
7.39+0.12
INSP
Inspire Medical Systems, Inc.
115.51-3.75
JSPR
Jasper Therapeutics, Inc.
1.71+0.07
MTNB
Matinas Biopharma Holdings, Inc
0.74+0.01
NTRB
Nutriband Inc.
4.49-0.35
PULM
Pulmatrix, Inc.
4.10-0.25
SEPSF
ASEP Medical Holdings Inc.
0.01+0.00
SPRY
ARS Pharmaceuticals, Inc.
10.66+0.07